विज्ञप्तियां उर्दू विज्ञप्तियां फोटो निमंत्रण लेख प्रत्यायन फीडबैक विज्ञप्तियां मंगाएं Search उन्नत खोज
RSS RSS
Quick Search
home Home
Releases Urdu Releases Photos Invitations Features Accreditation Feedback Subscribe Releases Advance Search
home  Printer friendly Page home  Email this page
English Release 23-August 2014
Date Month Year
  • President's Secretariat
  • President of India Condoles The Passing Away of U R Ananthamurthy
  • President calls upon IITs to play a pivotal role in developing newer cutting edge technologies
  • Prime Minister's Office
  • Prime Minister receives Tamil National Alliance delegation

Previous Date

 
Ministry of Chemicals and Fertilizers03-May, 2012 15:57 IST
Manufacturing of Generic Version of Drugs
The Government has recently decided to invoke the flexibility under the World Trade Organisation (WTO) agreement on trade related Intellectual Property Rights for compulsory licensing of patented drugs to ensure availability of patented drugs at affordable prices.

This was stated by the Minister of State for Chemicals and Fertilisers, Shri Srikant Kumar Jena in a written reply in the Lok Sabha today. He said the Department of Industrial Policy and Promotion has informed that so far one Compulsory license has been granted by the Controller General of Patents, Designs and Trade Marks to a drug manufacturing company since the amendment of the Patents Act in 2005 for an application filed under Section 84 of the Patents Act (as amended in 2005). The details are given as under:

• The Compulsory license has been granted by the Controller General of Patents, Designs and Trade Marks for the anti-cancer drug in which the compound is “Sorafenib Tosylate” (Patent No. 215758). The patent was granted to M/s Bayer Corporation, USA on 03.03.2008 by the Indian Patent Office, consequent to their filing a national phase application in India.

• M/s Bayer Corporation, USA developed the drug under trade name “NEXAVAR” and received regulatory approval for importing and marketing the drug in India and launched it in India in the year 2008.

• The Compulsory license for the drug has been granted to M/s Natco Pharma Ltd., Hyderabad, Andhra Pradesh.

As per the orders of the Controller of Patents, Mumbai compulsory license has been granted to M/s Natco for manufacture of “NEXAVAR”. M/s Natco Pharma Ltd. are required to sell this drug at a price not exceeding Rs. 8880/- for a pack of 120 tablets, required for a month’s treatment which was earlier being sold by M/s Bayer Corporation at Rs. 2,80,428/- for one month treatment.

DNM/AS
(Release ID :82984)

Web Ratana This site is winner of Platinum Icon for 'Outstanding Web Content' Web Ratna Award'09 presented in April 2010
Site is designed and hosted by National Informatics Centre (NIC),Information is provided and updated by Press Information Bureau
"A" - Wing, Shastri Bhawan, Dr. Rajendra Prasad Road, New Delhi - 110 001 Phone 23389338
Go Top Top

उपयोग संबंधी शर्तें स्वोत्वाधिकार नीति गोपनीयता संबंधी नीति हाइपरलिंकिंग नीति Terms of Use Copyright Policy Privacy Policy Hyperlinking Policy